Pharmacologic adjunctive to insulin therapies in type 1 diabetes:The journey has just begun |
| |
Authors: | Spyridon N Karras Theocharis Koufakis Pantelis Zebekakis Kalliopi Kotsa |
| |
Institution: | Spyridon N Karras, Theocharis Koufakis, Pantelis Zebekakis, Kalliopi Kotsa, Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki 55535, Greece |
| |
Abstract: | Treatment of type 1 diabetes(T1 D) is currently based exclusively on insulin replacement therapy. However, there is a need for better glycemic control, lower hypoglycemia rates, more effective weight management, and further reduction of cardiovascular risk in people with T1 D. In this context, agents from the pharmaceutical quiver of type 2 diabetes are being tested in clinical trials, as adjunctive to insulin therapies for T1 D patients. Despite the limited amount of relevant evidence and the inter-class variability, it can be said that these agents have a role in optimizing metabolic control, assisting weight management and reducing glycemic variability in people with T1 D. Specific safety issues, including the increased risk of hypoglycemia and diabetic ketoacidosis, as well as the effects of these treatments on major cardiovascular outcomes should be further assessed by future studies, before these therapeutic choices become widely available for T1 D management. |
| |
Keywords: | Type 1 diabetes Insulin Adjunctive therapies Cardiovascular risk |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《World journal of diabetes》浏览原始摘要信息 |
|